We want to hear from you!

The Canadian Agency for Drugs and Technologies in Health (CADTH) is conducting a drug review for an MS treatment called peginterferon beta-1a. Marketed as Plegridy(TM) by Biogen, this drug is a new formulation of interferon beta-1a that enables it to last longer in the body, reducing the dosing schedule.

We need people living with MS and caregivers to take part in this important initiative by providing feedback on the impact the drug has had on their MS, or the potential impact this drug could have on their MS or on the MS of someone they are providing care for.

You can submit feedback by completing the MS Society’s patient input survey. Your responses will help to inform important health care decisions surrounding public coverage for and access to MS treatments.

Categories Research

National vice-president, research, past MS researcher, and PhD in Cellular and Molecular Medicine from University of Ottawa. Leads the MS Society's research program to find the cure for MS and improve the quality of life for people affected by the disease.

Leave a Reply

Your email address will not be published.